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Abstract
Background: Coeliac disease is a common chronic autoimmune disorder. Underdiagnosis is common and the quality 
of life impact of symptoms may be severe. We report a study of symptom duration and quality of life before and after 
diagnosis in a representative sample of people with diagnosed coeliac disease in the UK.
Methods: Postal questionnaire of 2000 people with diagnosed coeliac disease, requesting information on date of 
diagnosis, type and duration of symptoms, and quality of life before and after diagnosis using the EQ-5D instrument.
Results: The survey response rate was 40% (788/2000). Mean duration of symptoms prior to diagnosis was 13.2 years, 
with some evidence of shorter duration in recent years. Respondents reported a mean of 13 consultations with their 
GP about their symptoms prior to diagnosis. The mean utility value of pre-diagnosis quality of life was 0.56, compared 
to 0.84 at time of survey, a highly statistically significant improvement of 0.27 (95% c.i. 0.25, 0.30).
Conclusions: The symptoms of undiagnosed coeliac disease are associated with a prolonged and substantial 
decrement to quality of life. These results strengthen the case for detailed examination of the cost-effectiveness of 
improved methods of detection and diagnosis, including population screening.
Background
Coeliac disease is a common chronic autoimmune disor-
der with a prevalence amongst adults and children
approaching 1% of the population in international studies
[1,2]. Underdiagnosis is common [3] and some studies
have reported frequent presentation with symptoms over
many years prior to diagnosis [4], although rates of diag-
nosis are increasing in many countries [5]. Once diag-
nosed, adherence to treatment involving the lifelong
elimination of wheat, rye and barley from the diet results
in significant clinical improvement for most patients. A
small number of studies have examined the quality of life
of coeliac patients, but these have typically focussed on
the quality of life of patients after diagnosis in relation to
the general population, and in particular on the impact of
a gluten free diet, and have relied on small samples and
instruments that do not facilitate comparison [6-8]. Here
we report on a survey of people with coeliac disease, in
which information was collected on the duration and
types of symptoms experienced prior to diagnosis, the
number of consultations about these symptoms prior to
diagnosis, and quality of life before and after diagnosis
using for the first time in this population the EQ-5D
instrument, a generic utility-based instrument that is
widely used in surveys and favoured in technology assess-
ment as it facilitates comparison across disease areas and
the general population [9,10]. We focus on comparisons
before and after diagnosis, but also examine whether the
introduction of serological testing, approximately
between 1993 and 2000 [5], altered characteristics at
diagnosis.
Methods
A representative sample of 2,000 individuals was drawn
from the membership list of Coeliac UK, the leading
charity working for people with coeliac disease and der-
matitis herpetiformis (DH) in the UK with a total mem-
bership of 70,000 or 56% of the estimated 125,000 people
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October 2007. A short questionnaire was designed, con-
taining questions on demographic characteristics, time
since diagnosis, type and duration of symptoms prior to
diagnosis, and quality of life before and after diagnosis,
using the EQ-5D questionnaire. Other data collected in
the questionnaire, for example on impact on daily activi-
ties and out-of-pocket costs associated with coeliac dis-
ease before and after diagnosis, are not reported here.
The symptom lists were devised based on existing litera-
ture, and revised following piloting of the questionnaire
with a local Coeliac UK members group. A copy of the
questionnaire accompanies this article [Additional file 1].
Where members were known to be under 18 years of
age, the parent or guardian was asked to complete the
questionnaire on behalf of or with the member. The ques-
tionnaire was publicised in the Coeliac UK Newsletter
sent to all members, and mailed with a covering letter and
prepaid return envelope to the sample. The sample
approached was stratified by each country of the UK,
postal town or county, and date of joining Coeliac UK.
Reminders to return the questionnaire were also publi-
cised in Coeliac UK newsletters. The survey was con-
ducted in 2007.
Data were entered onto a database, and a 10% sample
was double-entered to check whether any coding incon-
sistencies were concentrated in particular parts of the
questionnaire. These were then resolved by discussion
and re-examination of data.
No imputation was conducted to deal with missing
data, and results are presented using complete cases for
the relevant question or combination of questions. T-
tests were performed to assess whether missing cases
were significantly different from compete cases.
Responses to the EQ-5D questions were given a quality
of life valuation using the UK population tariff [11], and
were compared with population norms derived from a
national survey [12], having age- and sex-standardised to
the survey population. Proportions reporting no prob-
lems before diagnosis and now in response to each EQ-
5D question were compared using McNemar's chi-
squared test. Results were analysed in SPSS version 15.©
Data
788 of 2000 questionnaires were returned, a response rate
of just under 40%. The age and sex distribution of respon-
dents were compared with the Coeliac UK general mem-
bership and no statistically significant differences were
observed. The level of non-response varied from 2/788
(<0.5%) for presence of symptoms to 133/788 (17%) for
number of GP consultations prior to diagnosis.
Results
93% of respondents (728/783) were the only member of
their household with coeliac disease, with 7% sharing
their household with at least one other person diagnosed
with coeliac disease.
28% of respondents (220/777) were male and 72% (557/
777) female. The mean age (SD) of respondents was 52
(18) years, with a range from 2 to 89. 12% (97/777) of
respondents were aged less than 18 years, and 10% (80/
777) were aged 65 or over. On average respondents were
aged 41.3 years (SD 19) when they were diagnosed with
CD. The mean age at diagnosis was 39 (SD 18) for those
diagnosed before the year 2000, compared to 44 for those
diagnosed after 2000, a significant difference of 5 years
(95% ci 2.7 to 8.0).
Table 1 reports the frequency and duration of reported
symptoms prior to diagnosis. The most common symp-
toms were abdominal pain/bloating (71%), diarrhoea
(70%), anaemia (65%), chronic fatigue (62%), and weight
loss (61%). 78% of respondents (605/777) reported at least
4 symptoms, and only 1% (6/777) of respondents
reported no symptoms prior to diagnosis.
The mean duration of specific symptoms ranged from
12.6 years for constipation to 5.5 years for weight loss.
The average duration of any symptom before diagnosis
across the whole sample was 13.2 (SD 16.0) years. The
duration of symptoms in those diagnosed before and
after the year 2000 was 14.5 and 12.0 years respectively, a
significant difference of 2.5 years (95% CI 0.2. 4.9).
655 respondents (83%) provided information about the
number of times they had seen their GP about their
symptoms during the period prior to diagnosis, and Table
2 reports details. On average, respondents consulted their
GP 13.0 times about their symptoms. This was related to
duration of symptoms: those whose symptoms had lasted
for less than 1 year before diagnosis consulted GPs on
average 4.5 times for symptom related consultations,
whereas those whose symptoms had lasted for 20 or more
years had consulted their GP on average 27.7 times for
symptom related consultations. The average number of
pre-diagnosis visits to GPs about symptoms was 7.0
amongst those diagnosed after the year 2000 compared to
17.4 amongst those diagnosed before 2000, a mean differ-
ence of 10.4 visits (95% CI 2.3, 18.5). Adjusted for age of
respondent and duration of symptoms, this difference
remained a statistically significant 11.4 visits (95% CI 1.9,
20.8).
Table 3 reports the number and percent of respondents
at different levels of each of the 5 questions comprising
the EQ-5D, before and after diagnosis, and the corre-
sponding percentages at each level in the general popula-
tion of England. Results are shown for the 697 of 788
respondents (88%) completing EQ-5D questionnaires for
both their pre-diagnosis and their current health state.
In all five dimensions of the EQ-5D, the proportion of
respondents reporting no problems was significantly
higher at the time of the survey compared to before diag-
nosis: this was particularly pronounced in the pain
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problems at the time of the survey, compared to only 22%
prior to diagnosis of coeliac disease. The distribution of
responses from a large general population survey in Eng-
land, age- and sex-standardised to the survey respondent
population, is also shown in Table 3: across all five health
dimensions the proportion of respondents reporting no
problems before diagnosis was lower than in the general
population, but at time of survey was similar to or higher
than in the general population.
Placing valuations on these EQ-5D health states using
the British "tariff "11 (Table 4), the mean quality of life
before diagnosis was 0.56, (where 0 = death and 1 = full
health), and 0.84 at the time of the survey, indicating a
highly statistically significant improvement of 0.27 (95%
c.i. 0.25, 0.30). By comparison, the average quality of life
in the general population has been reported as 0.82 when
age-sex-standardised to age of respondents at time of sur-
vey response, or 0.85 when age-standardised to age of
respondents at age at diagnosis [12].
On the Visual Analogue Scale, respondents rated their
health at 47% before diagnosis (0 = worst imaginable
state, 100 = best imaginable state), and at 79% now, a
highly significant improvement of 32 (95% C.I. 30, 35)
percentage points.
Table 1: Frequency and duration of symptoms prior to diagnosis of coeliac disease.
Symptom: Number (%) reporting symptoms
(of 777 respondents)
Duration of symptoms (years)
Number % (95% CI) Mean (95% CI)
Any symptom 771 99 (98, 100) 13.2 (12.1, 14.4)
Abdominal pain/bloating 556 71 (67, 74) 7.9 (7.0, 8.7)
Diarrhoea 553 70 (67, 73) 6.9 (6.1, 7.8)
Anaemia 509 65 (61, 680 11.5 (10.5, 12.6)
Chronic fatigue 488 62 (59, 650 7.1 (6.3, 7.9)
Weight loss 479 61 (57, 640 5.5 (4.7, 6.2)
Flatulence 368 47 (43, 50) 9.5 (8.6, 10.4)
Mouth ulcer 236 30 (27, 33) 11.2 (10.1, 12.3)
Headache 232 30 (26, 33) 10.3 (9.3, 11.3)
Joint pain 220 28 (25, 31) 8.2 (7.4, 9.0)
Skin rash 208 26 (23, 30) 9.9 (8.9, 10.9)
Constipation 207 26 (23, 29) 12.6 (11.5, 13.6)
Depression 185 24 (21, 27) 9.2 (8.3, 10.1)
Other symptoms 163 21 (18, 24) 5.4 (4.8, 6.1)
Osteoporosis 91 12 (10, 14) 7.7 (6.7, 8.6)
Ataxia 39 5 (3, 7) 6.1 (5.2, 6.9)
No symptoms 6 1 (0, 2)
Table 2: Mean number of GP consultations pre-diagnosis about symptoms, by duration of symptoms.
Number of consultations
Duration of all symptoms in years: Mean N 95% CI
>1 4.5 106 (3.5, 5.5)
1-5 9.2 170 (4.1, 14.3)
5-10 8.4 79 (6.1, 10.7)
10-20 8.9 95 (6.5, 11.4)
>20 27.7 155 (11.4, 44.1)
Total 13.0 605 (8.5, 17.5)
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Page 4 of 7Table 3: Respondents' self-reported health on EQ-5D before diagnosis of coeliac disease (retrospective) and now: number 
and percent by level of response, and UK population norms (percent)*1.






N % N % N %
Mobility:
before diagnosis 524 75 159 23 14 2
Now 602 86* 93 13 2 0
UK population norm 78 22 0
Self-care:
before diagnosis 648 93 35 5 14 2
Now 673 97* 18 3 6 1
UK population norm 93 6 0
Usual activities:
before diagnosis 403 58 249 36 45 6
Now 574 82* 116 17 7 1
UK population norm 78 19 3
Pain:
before diagnosis 153 22 349 50 195 28
Now 416 60* 252 36 29 4
UK population norm 58 37 4
Anxiety/depression:
before diagnosis 351 50 259 37 87 12
Now 518 74* 163 23 16 2
UK population norm 75 23 2
*Proportion reporting no problem significantly different now compared to before diagnosis (McNemar-Bowker Chi-square test, p < 0.01)
1 UK population norms from Health Survey for England 1996, standardised to age distribution of Coeliac UK survey respondents now.
There was no clear evidence that the levels of health
reported by respondents before and after diagnosis was
related to duration of symptoms. Respondents who were
diagnosed prior to 2000 had a mean EQ-5D tariff of 0.55,
compared with 0.58 amongst those diagnosed after 2000,
a small but not statistically significant difference of 0.03
(95% C.I. -0.02, 0.08). Similarly, the VAS was slightly but
not significantly higher at diagnosis amongst those diag-
nosed after 2000 (49%) compared with those diagnosed
before 200 (46%) (mean difference 3, 95% C.I. -1, 6).
Figure 1 shows levels of health reported by respon-
dents, by age group, before diagnosis and at the time of
the survey. Levels of health were clearly related to age
before diagnosis, rising from 0.52 (95% C.I. 0.45, 0.58)
amongst those aged 18-34 when diagnosed to 0.71 (95%
C.I. 0.65, 0.78) amongst those aged 65 and over at diagno-
sis. No such differences between age groups were evident
in reported quality of life at time of survey. However, all
age groups reported a significant improvement in quality
of life at the time of the survey compared to the period
prior to diagnosis.
Discussion
In this study we have shown that the quality of life of peo-
ple with undiagnosed symptomatic coeliac disease is sub-
stantially reduced compared to the general population,
and increases markedly after diagnosis. The difference
(0.56 prior to diagnosis (where 0 = death and 1 = full
health) to 0.84 at the time of the survey), is quantitatively
similar to the quality of life impact of severe events such
as stroke [13].
Our study found a mean duration of symptoms of 13.2
years; although there was some evidence that this had
fallen since the widespread adoption of serological testing
in the 1990s, the mean duration of symptoms of those
diagnosed after the year 2000 was still 12 years. These
durations are similar to the 11 years with symptoms prior
to diagnosis reported in a large American study, which
also showed some evidence of reduced duration of symp-
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Table 4: Respondents' self-reported health on EQ-5D before diagnosis of coeliac disease (retrospective) and now: mean 
score on Visual Analogue Scale and mean tariff-based valuation of health state, and UK population norm1.
Mean 95% CI
EQ-5D tariff:
pre-diagnosis 0.56 (0.54, 0.59)
time of survey 0.84 (0.82, 0.85)
change 0.27 (0.25, 0.30)
UK population norm, standardised to age 
distribution of respondents at:
time of survey 0.82 (0.81, 0.83)
time of diagnosis 0.85 (0.84, 0.86)
Visual Analogue Scale:
pre-diagnosis 47% (45, 49)
time of survey 79% (78, 80)
change 32% (30, 35)
1 UK population norms from Health Survey for England 1996, standardised to age distribution of Coeliac UK survey respondents now.
Figure 1 Respondents' self-reported health on EQ-5D before diagnosis of coeliac disease (retrospective) and now: mean tariff-based valu-
ation of health state, by age at diagnosis.
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Page 6 of 7toms following the introduction of serological testing
[14].
Previous studies of quality of life associated with coeliac
disease have not focused on differences before and after
diagnosis, and have not used the EQ-5D. One advantage
of the EQ-5D is that it is a widely used generic quality of
life instrument that permits comparison across many dif-
ferent disease areas, and is therefore particularly useful in
assessing the comparative cost-effectiveness of a wide
range of different interventions: for this reason the EQ-
5D is the only quality of life instrument specifically rec-
ommended for calculating quality adjusted life years by
the National Institute of Health and Clinical Excellence in
its recommended methods for technology appraisal [10].
The EQ-5D derived estimates of utility before and after
diagnosis reported here, and the estimated duration of
symptoms prior to diagnosis, may be helpful in assessing
the cost-effectiveness of improved methods of screening
and detection; such studies to date have typically concen-
trated on cost per case detected [15], often in population
sub-groups [16] or have specifically excluded quality of
life due to the prior lack of reliable estimates [17]. A sys-
tematic review undertaken to inform the cost-effective-
ness modelling that formed part of the NICE Guidelines
on celiac disease published in 2009 was unable to find any
utility estimates in the literature at that time [18].
Our estimates of quality of life prior to diagnosis of coe-
liac disease are based on retrospective assessment; such
methods are unavoidable in the absence of very large
long-term prospective studies, and have been used before
with different instruments and in different disease areas
[19,20], but it is not known whether the results obtained
would be comparable with those derived from prospec-
tive studies, and there is a lack of information on this with
the EQ-5D or indeed other instruments. Similarly,
although there is no evidence that the respondents to this
survey were different to non-respondents, it is possible
that the population from which the sample was drawn -
members of Coeliac UK, stratified by area and duration of
membership - are in some way unrepresentative of the
entire population of those with diagnosed coeliac disease.
However, given the magnitude of the quality of life differ-
ences reported in this study, and given that the charity
has 56% of all diagnosed patients enrolled in its member-
ship, it seems unlikely that any recall or sampling bias
could seriously alter the results.
Conclusions
The symptoms of undiagnosed coeliac disease are associ-
ated with a prolonged and substantial decrement to qual-
ity of life. In light of these results, the case for detailed
examination of the cost-effectiveness of improved meth-
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